The Trastuzumab and Vinorelbine Combination: An Alternative to Taxane-Based Chemotherapy for Early-Stage and Locally Advanced HER2-Positive Breast Cancer
| Autor: | Cristiano Ferrario, Lawrence Panasci, Khashayar Esfahani, Philippe Le |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Short Communication medicine.medical_treatment Navelbine Neutropenia Vinorelbine her2-positivity Breast cancer Herceptin Trastuzumab Internal medicine medicine early breast cancer skin and connective tissue diseases Chemotherapy small tumours Taxane business.industry Cancer medicine.disease Surgery vinorelbine trastuzumab business Febrile neutropenia medicine.drug |
| Zdroj: | Current Oncology Volume 21 Issue 5 Pages 2069-727 |
| ISSN: | 1718-7729 |
| DOI: | 10.3747/co.21.2069 |
| Popis: | Anthracyclines and taxanes have historically constituted the backbone of chemotherapy regimens for patients with breast cancer positive for the human epidermal growth factor receptor 2 (her2). For a subset of patients who categorically refuse alopecia, or for those with a contraindication to those drugs, there is an urgent need to define alternative regimens. Here, we report our institutional experience with trastuzumab and vinorelbine (tv), a combination with good clinical activity and a good side effect profile for patients with her2-positive breast cancer. In a retrospective analysis, outcomes data were extracted for patients receiving tv as their only chemotherapy in the non-metastatic setting at the Jewish General Hospital. For the most part, tv was administered weekly for 6 months, followed by trastuzumab for 6 months. The analysis identified 46 patients (mean age: 64 years) who received tv between 2003 and 2012 (n = 36 adjuvant, n = 10 neoadjuvant). Of the patients in the adjuvant group, 81% had stage i disease. In the neoadjuvant group, 3 patients experienced a complete pathologic response. Only 1 patient experienced local recurrence after a short course (3 months) of adjuvant tv. Overall survival and breast cancer&ndash specific survival were 94% and 98% respectively at a median 5 years of follow-up. Febrile neutropenia&ndash induced sepsis resulted in the death of 1 patient with significant medical comorbidities 2 other patients died of comorbidities unrelated to their cancer or treatment. Grades 3 or 4 adverse events included neutropenia (23%), febrile neutropenia (10%), fatigue (2%), and anemia (2%). For patients with non-metastatic breast cancer refusing alopecia, or for patients who are not candidates for standard chemotherapy, tv is a reasonable alternative to standard adjuvant chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|